Complement-mediated TMA (cmTMA) can occur in the context of genetic or acquired defects in complement proteins (primary cmTMA) or in association with other disease processes like autoimmunity, medications, malignancy, and infection (secondary cmTMA). This evidence concerns the gene VTN and Autoimmunity.